ST. PAUL, Minn.--(BUSINESS WIRE)--Cardiovascular Systems, Inc. (CSI ®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients ...

Cardiovascular disease is the leading cause of death in the United States, claiming an estimated 1 million lives, and incurring a cost of $400 billion per year. Much of cardiovascular disease can be ...

“During Q4, we achieved strong sequential growth across all business segments with our U.S. peripheral and coronary atherectomy franchises growing 9% and 16% over prior quarter, respectively.

Once the acquisition is complete, Cardiovascular Systems' devices will join Abbott’s own range of vascular-disease-focused products. That’ll include the company's existing guidewires, catheters and ...

“We are pleased with the state of our business and our performance in the first quarter. Q1 revenue of $59.7 million represented 2.2% revenue growth compared to last year. Worldwide coronary revenue ...